Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

CONTEXT: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is typically treated with lifelong supraphysiologic doses of glucocorticoids (GCs). Tildacerfont, a corticotropin-releasing factor type-1 receptor antagonist, may reduce excess androgen production, allowing for GC dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarafoglou, Kyriakie, Barnes, Chris N, Huang, Michael, Imel, Erik A, Madu, Ivy-Joan, Merke, Deborah P, Moriarty, David, Nakhle, Samer, Newfield, Ron S, Vogiatzi, Maria G, Auchus, Richard J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530725/
https://www.ncbi.nlm.nih.gov/pubmed/34146101
http://dx.doi.org/10.1210/clinem/dgab438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530725/
https://www.ncbi.nlm.nih.gov/pubmed/34146101
http://dx.doi.org/10.1210/clinem/dgab438

Ejemplares similares